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Background: It is estimated that millions of North Americans would 
qualify for lung cancer screening and that billions of dollars of 
national health expenditures would be required to support popula-
tion-based computed tomography lung cancer screening programs. 
The decision to implement such programs should be informed by 
data on resource utilization and costs.
Methods: Resource utilization data were collected prospectively 
from 2059 participants in the Pan-Canadian Early Detection of 
Lung Cancer Study using low-dose computed tomography (LDCT). 
Participants who had 2% or greater lung cancer risk over 3 years 
using a risk prediction tool were recruited from seven major cities 
across Canada. A cost analysis was conducted from the Canadian 
public payer’s perspective for resources that were used for the screen-
ing and treatment of lung cancer in the initial years of the study.
Results: The average per-person cost for screening individuals with 
LDCT was $453 (95% confidence interval [CI], $400–$505) for the 
initial 18-months of screening following a baseline scan. The screen-
ing costs were highly dependent on the detected lung nodule size, 
presence of cancer, screening intervention, and the screening cen-
ter. The mean per-person cost of treating lung cancer with curative 
surgery was $33,344 (95% CI, $31,553–$34,935) over 2 years. This 
was lower than the cost of treating advanced-stage lung cancer with 
chemotherapy, radiotherapy, or supportive care alone, ($47,792; 95% 
CI, $43,254–$52,200; p = 0.061).
Conclusion: In the Pan-Canadian study, the average cost to screen 
individuals with a high risk for developing lung cancer using LDCT 
and the average initial cost of curative intent treatment were lower 
than the average per-person cost of treating advanced stage lung can-
cer which infrequently results in a cure.
Key  Words: Lung cancer screening, Cost analysis, Cost-effectiveness.
(J Thorac Oncol. 2014;9:1449–1458)
The National Lung Screening Trial (NLST) demonstrated a 20% reduction in lung cancer-specific mortality by screen-
ing high-risk current or former smokers in the United States 
using low-dose computed tomography (LDCT).1 The NLST 
is the first randomized trial with adequate power and duration 
of follow-up to demonstrate the absolute benefits of LDCT 
screening. Incorporating results of the trial, the U.S. Preventive 
Services Task Force gave a grade B recommendation for lung 
cancer screening using LDCT in the United States.2
The potential impact that lung cancer screening may 
have at the population-level is profound. It is estimated that 
in 2013, over 300,000 North Americans were diagnosed with 
lung cancer and approximately 200,000 died from the dis-
ease.3,4 With such high incidence and mortality rates, screen-
ing individuals for lung cancer with LDCT has the potential 
to save thousands of lives. Approximately 8.6 million indi-
viduals in the United States meet the criteria for enrolment in 
the NLST, based on their age and smoking history.5 The cost 
of national screening programs could be significant, poten-
tially reaching billions of dollars of national expenditure.6 
It is against this backdrop that an understanding of the costs 
associated with population-based LDCT screening becomes 
essential in order to estimate the budget impact of lung cancer 
screening programs.
Cost-effectiveness evidence in the literature for lung 
cancer screening with LDCT is inconclusive. Some models 
predict that LDCT-based screening is highly likely to be con-
sidered cost-effective while others conclude the opposite.7 
There are no models that use cost data from the actual experi-
ence of screening participants and little is known about the 
cost implications of screening, even in the idealized clinical 
trial setting. Screening costs may, for example, be skewed 
toward different individuals for a variety of reasons includ-
ing their general health and the availability of local healthcare 
resources.8 Diagnostic imaging rates and invasive procedures 
triggered by “positive” screening results can vary substantially 
between the different screening studies.9 The proportion of 
screened subjects affected by this uncertainty is considerable 
as data from both of the existing large randomized screening 
trials, (the NLST and the Dutch-Belgian Randomized Lung 
Cancer Screening trials) show that 20% or greater of those 
screened require at least one additional follow-up LDCT scan 
after their first baseline screening exam.10,11 The screening 
programs are driven by the hypothesis that lung cancer may 
be cured if the disease is detected at an early stage and that 
the benefits of doing so not only include reduced lung can-
cer mortality but also the possibility of averting potentially 
expensive treatment courses that are associated with low suc-
cess rates in the advanced stage setting.
The Pan-Canadian Early Detection of Lung Cancer 
Study was established with the objective of developing an 
affordable screening strategy for reducing lung cancer deaths 
within Canadian health care systems. The study selected indi-
viduals using a Web-based lung cancer risk prediction tool.12 
If that risk was 2% or more over 3 years, the participants were 
invited for an interview by a study coordinator at the screening 
center for inclusion in the study. In this article, we describe 
the resources utilized and the costs associated with the initial 
years of this screening study and 2 years of follow-up after 
the treatment of screen-detected lung cancer. Our intent is to 
improve the evidence base that is available for cost-effective-
ness modeling.
MATERIALS AND METHODS
The Pan-Canadian Study
Between September 2008 and December 2011, partici-
pants in the Pan-Canadian study were recruited by newspa-
per, radio, and physician office advertisements in seven major 
cities across Canada. The advertisements were directed to 
Canadians at the risk of developing lung cancer due to their 
age and smoking history. Inclusion/exclusion criteria and 
study methods have been reported previously.13
Following approval by the ethics review board at each 
of the recruiting institutions, 2537 eligible participants were 
enrolled and scheduled for screening with at least two annual 
LDCT screening tests (CT-S-1 and CT-S-2). The first half of 
the Pan-Canadian cohort also received a baseline autofluores-
cence bronchoscopy (AFB) screening exam. Lung nodules 
that were deemed suspicious for lung cancer were referred 
for further investigation, which may have included diagnos-
tic imaging, bronchoscopy, percutaneous biopsy, or a surgical 
procedure.
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Lung Nodule Follow-Up Protocol
Subjects with baseline scans (CT-S-1) with no nodules 
or with the largest solid nodule measuring less than 5 mm in 
diameter or nonsolid (ground glass) nodules, measuring less 
than 8 mm in diameter, were to undergo a follow-up exami-
nation in 12 months’ time (CT-S-2). If there were nodules 
on CT-S-1 or CT-S-2 but no new nodules and no growth of 
existing nodules on CT-S-2, a 24-month scan (CT-S-3) was 
performed. The subject was then discharged from the study 
at 12 months following CT-S-2 if there were no nodules at 24 
months, if there was no growth of existing solid nodules and 
no development of new nodules. Subjects with any semi-solid 
or solid nodule 5 to 10 mm or nonsolid nodules 8 to 10 mm 
were to receive an additional limited or low-dose full chest 
scan at 3 months (CT-S-n-FU).
A subject with growth of an existing nodule, develop-
ment of a solid component in a nonsolid nodule or a new nodule 
was to receive an additional scan at 3 months with a decision 
on successive scans, biopsy, or excision biopsy to be made at 
the discretion of the study physician and radiologist. A nodule 
that grew on two consecutive scans, a nonsolid opacity show-
ing development of a solid component and any nodule greater 
than 10 mm in diameter would be considered as suspicious for 
lung cancer and the lesion was managed based on the practice 
patterns of the local institution. Any other abnormality on the 
CT in the surrounding soft tissue of the chest and abdomen was 
followed according to the standard of care in the institution as 
directed by the medical team and the local study radiologist.
Resource Utilization Data
Study coordinators recorded demographic information, 
screening test results, and resource utilization data for enrolled 
participants on an electronic case report form. All direct medi-
cal healthcare resources used for early detection, diagnosis, 
staging, and treatment of lung cancer or any other type of can-
cer were recorded chronologically from the point of enroll-
ment in the study to the point of data censoring described in 
the “screening-phase parameters” section. The resources were 
defined as any medical appointment, investigation or proce-
dure, hospital admission, lung cancer treatment including 
chemotherapy, radiation therapy, surgery, or blood product 
used in the investigation or treatment of lung cancer and its 
sequelae. Resources used for clinical correlation of abnormal 
screening results, for complications arising from diagnostic 
tests, for lung cancer treatment or further screening were also 
included. Data on resources used to investigate or treat non-
cancer incidental findings such as coronary artery calcifica-
tion or emphysema were collected for a separate publication, 
but were not included in this cost analysis.
Screening Resources
Under the Pan-Canadian Study protocol, each partici-
pant was scheduled to receive at least two annual CT screen-
ing tests (CT-S-1 and CT-S-2). CT-S-1 was the first (baseline) 
screening exam and CT-S-2 was the second annual screen-
ing exam, occurring 12 months after CT-S-1. CT scans were 
classified as screening CT exams if they were undertaken 
according to the screening protocol (i.e., <1.5 mSv effective 
radiation dose, performed in the absence of a proven malig-
nancy, without intravenous contrast media, and conducted at 
least 60 days after the previous screening CT). The follow-
up screening exams were accounted for cumulatively; that is, 
the first follow-up screening LDCT triggered by CT-S-1 was 
termed CT-S-1-FU-1, and the second was CT-S-1-FU-2.
Screening-Phase Parameters
Resource utilization data for the screening phase com-
menced upon the date of CT-S-1 and continued for 18 months 
for the participants who did not have cancer. Data for par-
ticipants who had cancer were classified as “screening-phase” 
data until a cancer diagnosis was confirmed by biopsy or sur-
gical excision or 18 months of time from CT-S-1 had passed, 
whichever occurred first. A diagnosis of cancer needed to be 
documented within 30 months of CT-S-1 and before December 
31, 2012 to be captured in this analysis.
Treatment-Phase Resources
Resource utilization data for the treatment of lung can-
cer were analyzed separately as treatment-phase resources. 
The data were divided into four sub-phases of treatment: 
diagnostic workup, first-line treatment, follow-up year 1 and 
follow-up year 2. The data were sorted further according to 
the modality of first-line treatment (i.e., surgery or nonsur-
gical management) in order to represent the policy decision 
problem related to treating lung cancer with a curative intent. 
Resource utilization data for the diagnostic workup phase 
began at CT-S-1 and continued up to the date of the first che-
motherapy or radiotherapy treatment, date of surgery, or the 
date on which a decision was made for management by sup-
portive care only. Resources utilized during the first-line treat-
ment-phase were collected starting from the date of surgery 
or first chemotherapy or radiotherapy treatment and contin-
ued until the final day of first-line treatment, or 30 days after 
the surgery. Resources for complications were included in the 
first-line treatment phase until the complication resolved or 
the patient died, whichever occurred first. First-line treatment 
costs for patients who received supportive care only were set 
to zero and any subsequent resource utilization data were 
accounted for in the annual follow-up phases of treatment. 
Annual follow-up transitions occurred 365 days after the pre-
vious transition and resource utilization data for each com-
pleted phase of treatment including any relapsed lung cancer 
were included before December 31, 2012.
Cost Analysis
Resource utilization rates were multiplied by their cal-
culated unit cost and divided by the number of participants 
in the cohort to determine the mean per-person cost. The 
unit costs for resource utilization were based on the provin-
cial 2013 reimbursement schedules from the Medical Service 
Plan in the province of British Columbia. Physician fees 
and reimbursement for clinical services within Canada do 
not vary greatly for different provinces. Chemotherapy drug 
costs were referenced from Canadian wholesale drug prices. 
Hospitalizations for surgical resections, surgical pathol-
ogy, chemotherapy, radiotherapy, palliative care, ambulatory 
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care, and complications resulting from the procedures were 
accounted for on a per-person basis using hospital data from 
the province of Ontario and professional fees from the Medical 
Service Plan (see supplementary material, Supplemental 
Digital Content, http://links.lww.com/JTO/A661). All costs 
were inflated to 2013 Canadian dollars. One Canadian dollar 
was approximately equal to one U.S. dollar in 2013.
Statistical Analysis
Two regression models were built to investigate the 
impact of study variables (listed in Table 1) on screening 
resources. Model 1 is a logistic regression model to investi-
gate the factors that influence the use of CT-S-1-FU-1. The 
first follow-up CT exam was considered a representative 
additional screening resource that would be required beyond 
annual LDCT scans. Model 2 is a linear regression model 
with per-person screening costs as the dependent variable. The 
same independent variables were included in both the regres-
sion models. Clustering of data within study sites was han-
dled in regression modeling by treating them as fixed effects 
and including them in all the models as indicator variables. 
Postmodel building, interactions amongst regression variables 
was tested. Variables that were considered clinically relevant 
were included in the models (Table 3). Mann–Whitney signifi-
cance tests were applied to investigate statistically significant 
cost differences between treatment modalities. All statistical 
analyses were conducted with STATA version MP12.1.
RESULTS
Study Cohort
Two thousand fifty-nine participants of the 2537 pan-
Canadian participants were included in this analysis according 
CT-S-1 test results
  Number of nodules  
 (per-person)
3 (3.9)
  Nodule size
   1–4.9 mm nodule 1560 (75.8)
   5.0–9.9 mm nodule 827 (40.2)
   10.0–14.9 mm nodule 143 (7.0)
   Nodule(s) ≥15 mm 85 (4.1)
  Nodule characteristics
   ≥1 Calcified nodule 398 (19.3)
   ≥1 PFN 49 (2.4)
   ≥1 GGO 521 (25.3)
   ≥1 Semisolid 194 (9.4)
   ≥1 Solid nodule 1520 (73.8)
  Emphysema observed on 
CT-S-1
1195 (58.0)
aBaseline CT scan (CT-S-1).
LDCT, low-dose computed tomography; AFB, autoflourescence bronchoscopy; CT, 
computed tomography; COPD, chronic obstructive pulmonary disease; FEV1, forced 
expiratory volume in 1 sec; PFN, perifissural nodule; GGO, ground glass opacity.
TAbLE 1.  Demographic, Study, and Clinical Characteristics
Frequency-Discrete 
Variables (%)
Median-Continuous 
Variables (SD)
Demographic
  All 2059 (100)
  Age at CT-S-1, per yeara 62.9 (5.8)
  Female sex 915 (44.4)
  White ethnicity 1999 (97.1)
  Education, per level (1–7) Level 4 (1.7)
  Quality of life at baseline  
  (EQ5D visual analogue  
scale, <60% vs. ≥60%)
297 (14.4)
Study-specific
 Screening study site
  1 438 (20.1)
  2 339 (16.5)
   3 191 (9.3)
   4 264 (12.8)
   5 202 (9.8)
  6 362 (17.6)
   7 263 (12.7)
  Screening status
   18-months completed, no  
 cancer
1845 (89.6)
   Lost to follow-up 106 (5.1)
   Positive for lung cancer 83 (4.0)
   Other cancer 15 (0.7)
   Deceased 10 (0.5)
  Use of AFB-screening  
  intervention (LDCT +  
AFB vs. LDCT alone)
1184 (57.5)
  Number of chest radiographs  
  in the 1 year before  
enrolment
0 (0.7)
  Number of CT exams in the  
  past 3 years before  
enrollment
0 (0.2)
  Screening phase  
  (start-up phase [pre-2010]  
vs. full functioning phase 
[2010])
1278 (62.1)
Risk factors
  Pack years 50 (23.4)
  Smoking status, current  
 vs. former
1281 (62.2)
  Family history, first degree  
 relative with cancer
722 (35.1)
  Number of listed  
 comorbidities
3 (2.3)
  Presence of coronary heart  
 disease
150 (7.2)
  Presence of COPD 228 (11.1)
  Number of lung cancer  
 symptoms
3 (2.1)
  Presence of low lung function  
  (predicted FEV1 <80% vs. 
≥80%)
912 (44.3)
(Continued)
TAbLE 1. Continued
Frequency-Discrete 
Variables (%)
Median-Continuous 
Variables (SD)
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to the inclusion/exclusion criteria (Fig. 1). The number of 
individuals who did not have lung cancer detected was 1961 
and their median follow-up time was 547 days (interquartile 
range [IQR], 546–549). After 375 median days (IQR, 105.5–
546.8), 107 individuals were lost to follow-up. The main rea-
sons for loss from the study were that the participants had 
moved, developed other medical conditions or loss of interest 
when the prior LDCT did not show any suspicious abnormal-
ity. During the screening study period, 83 individuals (4%) 
had a lung cancer diagnosis confirmed within 244 median 
days (IQR, 78.5–522.0) following CT-S-1. Eighty-five per-
cent (1751) individuals who had CT-S-1 returned for CT-S-2 
within 370 median days (IQR, 361–385). Nine individuals 
died of nonlung cancer causes.
Screening-Phase Resources
The majority of screening-phase resources used in this 
study were LDCT screening exams: 32.5% of all screened 
individuals had at least one follow-up LDCT. Follow-up 
LDCT rates after CT-S-2 (i.e., CT-S-2-FU-1) were low (6.6%) 
and occurred within 98 median days following CT-S-2 (IQR, 
91–126), suggesting that most suspicious nodules are found 
on the initial baseline scan. Eighty-five percent of the individ-
uals who had CT-S-1 returned for CT-S-2 within 18 months; 
thus, less CT-S-2 resources were utilized. The lower rate of 
CT-S-2 utilization resulted in a lower contribution to the mean 
per-person cost over the 18-month screening period (Table 2). 
There were low rates of complications and low rates of inva-
sive investigations during the screening phase. Physician and 
diagnostic resources were rarely utilized for screening that 
did not result in a cancer diagnosis and screening occurred 
mostly outside of the primary care setting. There were 14 phy-
sician appointments per 100 persons screened overall, con-
tributing an average $20 to the mean per-person cost of the 
entire cohort. Individuals who had lung cancer had an average 
of 1.4 physician appointments before their lung cancer was 
confirmed.
The mean per-person cost of screening individuals who 
did not have a lung cancer diagnosis was $453 (95% confi-
dence interval [CI], $400–505) for individuals screened with 
LDCT. For individuals who were screened with AFB and 
LDCT, the average screening cost was significantly higher as 
a result of the high unit cost of AFB resources.
The use of AFB screening interventions did not affect the 
use of the most commonly used resource, CT-S-1-FU-1, but it 
was a statistically significant contributor to increased screen-
ing costs (p < 0.001), as shown in models 1 and 2 (Table 3). 
Study site, screening adherence status, smoking status and the 
number, size, and character of the nodules were significantly 
independent variables associated with CT-S-1-FU-1 rates and/
or increased screening cost (p < 0.05). All study sites showed 
significant differences from the reference site according to the 
use of CT-S-1-FU-1 resources and four of six study sites had 
significantly higher cost coefficients than the reference site.
Treatment-Phase Resources
There were 83 lung cancer cases detected and confirmed 
within 30 months of CT-S-1. Sixty-seven percent of these 
cases were stage IA non–small-cell lung cancer (NSCLC), 
and 75% were early-stage (I or II) NSCLC (Fig. 1). The aver-
age per-person cost to find and diagnose lung cancer was not 
statistically significantly different between individuals who 
had first-line surgery versus nonsurgical treatment (p = 0.74) 
nor were the treatment-phase costs different between the two 
groups (p = 0.13; Table 4). Bronchoscopy, physician and imag-
ing resource utilization rates drove the average cost higher (p 
< 0.05) in the nonsurgical diagnosis and treatment phases and 
the mean cost to treat serious complications was higher for the 
patients treated with first-line surgery (p < 0.05). The chemo-
therapy drug costs in this study were only for cytotoxic, non-
targeted agents (see supplementary material, Supplemental 
Digital Content, http://links.lww.com/JTO/A661).
The annual follow-up costs were statistically signifi-
cantly lower for the individuals who received first-line surgery 
when compared with those who received nonsurgical treat-
ment for the advanced-stage disease in years 1 and 2 (p < 0.001 
and p < 0.05, respectively). The cumulative, mean per-person 
cost for individuals diagnosed with cancer who completed all 
FIgURE 1.  Economic analysis of the Pan-Canadian Early 
Detection of Lung Cancer Study. NSCLC, non–small-cell lung 
cancer; CT, computed tomography.
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four phases of treatment (diagnostic workup, treatment, fol-
low-up year 1 and follow-up year 2) or died was $33,244 (95% 
CI, $31,553–34,935), for individuals who received surgery as 
their first-line treatment (n = 38). Eighteen percent (6 of 33) 
of individuals who completed all four phases of treatment and 
had early-stage NSCLC (<stage III) had radiographic and/
or pathologic evidence of recurrent or second primary lung 
cancer within 2 years of their surgery. The cumulative cost 
of treating individuals with surgery over all the four treat-
ment phases was lower than the cumulative cost of treating 
advanced-stage lung cancer with chemotherapy, radiotherapy, 
or supportive care alone (n = 15) ($47,796; 95%CI, $43,258–
52,265) (p = 0.061, comparing the two costs).
DISCUSSION
This is the first prospective resource utilization and cost 
analysis of a lung cancer screening study that may be used 
to inform program evaluation and cost-effectiveness analyses 
(CEAs). We noted that nodule management differed between 
the study sites, which contributed significantly to the cost of 
follow-up after the baseline CT scan and to increased screen-
ing costs at some of the study sites. Our results project the 
expected 18-month screening costs for an LDCT-based study 
of 1000 people to be $434,427 to screen participants who do 
not have lung cancer at the baseline or within 18 months of 
follow-up. If the cancer detection rates and treatment deci-
sions were similar to those observed in the Pan-Canadian 
study (i.e., 4% screen-detected lung cancer, 81% receiving 
first-line surgery, 19% receiving nonsurgical first-line treat-
ment for advanced disease), the expected cost for the treatment 
of screen-detected lung cancer would total over $1.4 million 
dollars. The entire program, including both LDCT-based 
screening and treatment costs for 1000 subjects, would cost 
approximately $1.9 million dollars or $1880 per person. This 
excludes the initial costs of setting up the screening program 
infrastructure and its promotion through the general practice 
and wider community. Recruitment costs were not included 
in our cost analysis although the centers were provided with a 
research budget of $20,000 to use toward advertising or other 
recruitment strategies. Recruitment in the NLST was reported 
to cost an average $130 (USD) per-person.14
When the findings of the Pan-Canadian study are com-
pared with the NLST, the same low rate of invasive investiga-
tions and complications is observed in screened individuals 
without lung cancer.10,15 However, in the Canadian study, there 
is a slightly higher rate of follow-up CT exams than in the 
TAbLE 2.  Mean Per-Person Cost (SE) for Screening-Phase Costs
Resource
All Screened (Cancer Detected 
+ No Cancer Detected)
No Cancer Detected
Lung Cancer Detected Other Cancer DetectedAFB + CT Screened CT Screened
Number 2059 1140 821 83 15
CT-S-1a $193 (0) $193 (0) $193 (0) $193 (0) $193 (0)
CT-S-2b $165 (2) $180 (1) $154 (3) $77 (10) $77 (25)
Follow-up LDCTc
  CT-S-1-FU-1 $44 (2) $49 (2) $33 (2) $77 (9) $53 (20)
  CT-S-1-FU-2 $6 (1) $7 (1) $3 (1) $22 (7) $11 (11)
  CT-S-1-FU-3 $1 (0) $1 (0) — $4 (3) $0 (0)
  CT-S-2-FU-1 $11 (1) $13 (1) $7 (1) $15 (5) $32 (17)
  CT-S-2-FU-2 $0 (0) $0 (0) $0 (0) $0 (0) $0 (0)
Screening AFB $427 (8) $742 (1) — $358 (42) $201 (89)
Non-invasive investigations
  Diagnostic imaging $44 (6) $15 (5) $13 (4) $711 (92) $302 (134)
  Physician $20 (2) $16 (2) $6 (1) $192 (25) $162 (43)
  Cardiopulmonary exams $3 (1) $1 (0) $0 (0) $58 (13) $9 (6)
Invasive investigations
  Endoscopy $36 (4) $26 (5) $11 (4) $302 (57) $625 (228)
  Percutaneous biopsy $20 (3) $4 (2) $3 (2) $384 (61) $185 (101)
  Surgery (benign lesion) $26 (12) $27 (16) $29 (21) n/ad n/ad
Complications
  Minor $1 (1) $2 (1) — $7 (5) $0 (0)
  Intermediate $5 (3) — — $208 (111) $0 (0)
 Hospitalization $9 (9) — — — $1212 (1212)
Average cost (per-person) $1011 (22) $1275 (21) $452 (27) $2606 (178) $3062 (1176)
aBase line scan (CT-S-1).
b12-month annual scan (CT-S-2).
c3-month follow-up scan (CT-S-n-FU-n).
dNot applicable because surgery for proven malignant lesions are classified as treatment-phase resources.
SE, standard error; AFB, autoflourescence bronchoscopy; CT, computed tomography.
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NLST after the first (baseline) LDCT (32.5% versus 21%), yet 
the rates of follow-up CT exams that occurred after CT-S-2 
were similar, 6.6% and 7.1%, for the Canadian and NLST 
studies, respectively. A recently reported lung nodule malig-
nancy risk calculator has the potential to reduce variability in 
workup at screening sites and substantially reduce the number 
of CTs after the first screening LDCT.13
Our data also show that treatment costs are a substantial 
component of any lung cancer screening program and should 
be considered in detail in CEA, particularly as new chemo-
therapeutic agents emerge and drive late-stage treatment costs 
higher.16 In Canada, cancer treatments generally cost less than 
in the United States and the price of patented drugs in Canada 
is contained by the government regulation, which ensures 
that new drugs are not sold at a price higher than the mean 
price in comparable member countries of the Organization for 
Economic Co-operation and Development.17
There has been considerable debate surrounding the 
issue of cost-effectiveness of lung cancer screening, due 
largely to the absence of evidence of a mortality benefit before 
the NLST. Some studies have found that lung cancer screening 
is likely to be cost-effective.18–21 Others, including post-NLST 
simulations, have found that screening with LDCT would be 
highly unlikely to be considered cost-effective, even under the 
most conservative parameter inputs.22,23 Smoking cessation 
interventions can improve the cost-effectiveness of screening 
programs.19,23 None of the studies to date have considered real 
world screening study data. The current challenge in health 
care delivery is how to exploit new technologies to improve 
patient outcomes and improve health care access, while keep-
ing the costs under control. The number of deaths that poten-
tially could be prevented and the number of life years gained 
TAbLE 3.  Regression Modeling: Covariates Associated with 
the Use of CT-S-1-FU-1 (Model 1) and Increased Screening-
Phase Cost (Model 2)
Model variables Model 1 Model 2
Dependent variables Odds ratio (SE) Cost coefficient (SE)
  Outcomes CT-S-1-FU-1 Screening-phase cost
Independent variables
Demographic
  Age at CT-S-1, per year n.s. n.s.
  Female sex n.s. n.s.
  White ethnicity n.s. n.s.
  Education, per level n.s. n.s
  Quality of life at baseline,  
 EQ5D visual analog scale  
 <60% vs. ≥60%
n.s. n.s.
Study-specific
  Screening study site
   1 Reference Reference
   2 2.18 (0.33)*** $303*** (81)
   3 2.62 (0.35)*** n.s.
   4 2.71 (0.34)*** $175* (79)
   5 2.37 (0.37)*** n.s.
   6 2.40 (0.29)*** $217** (70)
   7 1.16 (0.32)*** $156* (79)
  Screening status
   18-months completed,  
 no cancer
Reference Reference
   Lost to follow-up −0.98* (0.49) −$226* (93)
   Positive for lung cancer −1.24** (0.36) $1340*** (112)
   Other cancer −1.74* (0.74) $2089*** (245)
   Deceased −3.86* (1.52) n.s.
  Use of AFB screening  
  intervention (LDCT + 
AFB vs. LDCT alone)
n.s. $700*** (50)
  Number of chest  
  radiographs in the 1 
year before enrolment
n.s. n.s.
  Number of CT exams in  
  the past 3 years before 
enrollment
n.s. n.s.
  Screening phase (start-up  
  phase [pre-2010] vs. full 
functioning phase [2010])
n.s. n.s.
Risk factors
  Pack years n.s. n.s.
  Smoking status, current  
 vs. former
0.34 (0.17)** n.s
  Family history, first degree 
 relative with cancer
n.s. n.s.
  Number of listed  
 comorbidities
n.s. n.s.
  Presence of coronary  
 heart disease
n.s. n.s.
  Presence of COPD n.s. n.s.
  Number of lung cancer  
 symptoms
n.s. n.s.
  Presence of low lung  
  function (predicted FEV1 
<80% vs. ≥80%)
n.s. n.s.
(Continued  )
CT-S-1 test results
  Number of nodules  
 (per-person)
0.12 (0.03)*** n.s.
  Nodule size
   1–4.9 mm nodule −0.53*** (0.28) n.s.
   5.0–9.9 mm nodule 3.6*** (0.21) n.s.
   10.0–14.9 mm nodule 3.0*** (0.31) $500*** (82)
   nodule(s) ≥15 mm 1.6*** (0.36) $542* (108)
  Nodule characteristics
   ≥1 Calcified nodule −0.88*** (0.23) n.s.
   ≥1 PFN n.s. n.s.
   ≥1 GGO −0.52** (0.19) −$154** (54)
   ≥1 Semi-solid n.s. n.s.
   ≥1 Solid nodule 0.92** (0.29) $136* (69)
  Emphysema observed on  
 CT-S-1
n.s. n.s.
p ≥ 0.05, *p < 0.05, **p < 0.01, ***p < 0.001.
n.s., not significant; SE, standard error; AFB, autoflourescence bronchoscopy; 
LDCT, low-dose computed tomography; COPD, chronic obstructive pulmonary disease; 
FEV1, forced expiratory volume in 1 sec; PFN, perifissural nodule; GGO, ground glass 
opacity.
TAbLE 3. Continued
Model variables Model 1 Model 2
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with lung cancer screening using LDCT is greater than any 
new treatment modality offered over the last 2 decades. If 
expensive targeted therapies become widespread in the treat-
ment of advanced, inoperable lung cancer, a screening pro-
gram could potentially become cost saving while at the same 
time improving patient outcomes.
Continuing care for stage III and IV lung cancer is higher 
than early-stage lung cancer on a monthly basis, even when 
chemotherapy costs are excluded.24 Data from the Canadian 
National Ambulatory Care Reporting System in Canada also 
suggest high costs of care to manage advanced lung cancer 
specifically due to the use of acute inpatient, intensive care, 
and emergency department resources in the last month of 
life.25 The Canadian data also shows that the number of deaths 
that occur in an acute care hospital is nearly three times higher 
for lung cancer than for any other type of cancer.
Shifting lung cancer management toward a “cura-
tive intent” paradigm would have cost consequences such 
as the additional treatment of overdiagnosed lung cancer 
and the treatment for relapsed or second primary lung can-
cer, following a curative intent resection. Overdiagnosis of 
individuals who would not have died of the disease is esti-
mated to be approximately 13%.26 Surgical failure rates for 
early-stage NSCLC, as measured by recurrence or second 
lung primaries were 18% over the first 2 years, which were 
included in our study. However, the rate could potentially 
reach 40% over 5 years, and add costs to individuals who 
were treated initially with surgery.27 The collection of indi-
vidual cost and outcomes data in pilot screening studies is 
essential as screening guidelines, risk stratification and evi-
dence to inform cost-effectiveness estimates develop in the 
post-NLST era.
The Pan-Canadian study has potential limitations. The 
majority of the study participants were of Caucasian ethnicity 
and able to attend screening appointments at major Canadian 
cities. Depending on how rural and minority groups are 
reached, the actual program cost may be higher. In Canada, 
19% of the population lives outside of an urban community 
and 16% of the total population is a visible minority,28,29 pos-
sibly affecting screening adherence rates and out-of-pocket 
expenditures that are not covered by Canada’s healthcare 
programs. These costs were not included in this analysis. The 
impact of screening on the quality of life or other health out-
comes and noncancer incidental findings was not part of this 
analysis and we did not compare our results to a screen-free 
comparative cohort. The Pan-Canadian study was conducted 
prospectively through a multicenter, interdisciplinary network 
of lung cancer specialists in a healthcare system based on uni-
versal coverage. A population-based program may have higher 
costs and worse outcomes if screening does not involve a team 
that is experienced in the management of screen-detected lung 
nodules and treatment of early lung cancer. Reimbursement 
deficiencies could be problematic to patients in other health 
care systems if the patients have medical coverage for lung 
cancer screening but not for the treatment of detected disease.
The Pan-Canadian study has potential strengths. The 
risk prediction tool used in the Pan-Canadian study for recruit-
ment resulted in a reduction in the number of people needed 
to be screened to detect one lung cancer compared with NLST 
criteria. The risk prediction tool used in this study was subse-
quently found to have 11.9% greater sensitivity in identify-
ing those who would be diagnosed with lung cancer in the 6 
years of follow-up when compared with the NLST criteria.30 
Screening of higher risk individuals may also improve cost-
effectiveness by reducing the number of false positives per 
prevented lung cancer death.31
As program planning unfolds in publicly funded health-
care systems or private screening clinics, robust CEA model-
ing from both the public payer and societal perspective are 
necessary. The importance of building CEA models with ref-
erence to population-level data cannot be overstated. Lung 
cancer screening is going to be a major policy issue and accu-
rate information on the costs and benefits of screening are 
urgently needed to inform future cost-effectiveness models 
and the overarching policy debate.
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